Ensitrelvir

Ensitrelvir
Clinical data
Trade names	Xocova
Other names	S-217622
Routes of; administration	By mouth
ATC code	J05AE11 (WHO) ;
Legal status
Legal status	JP: Rx-only;
Identifiers
	IUPAC name 1-(2,4,5-Trifluorobenzyl)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-1,3,5-triazinane-2,4-dione;
CAS Number	2647530-73-0; 2757470-18-9;
PubChem CID	162533924;
UNII	PX665RAA3H;
KEGG	D12353;
Chemical and physical data
Formula	C22H17ClF3N9O2
Molar mass	531.88 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cn1cnc(CN2C(=O)N(Cc3cc(F)c(F)cc3F)C(=N\c3cc4cn(C)nc4cc3Cl)\NC2=O)n1;
	InChI InChI=1S/C22H17ClF3N9O2/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24/h3-7,10H,8-9H2,1-2H3,(H,28,29,36); Key:QMPBBNUOBOFBFS-UHFFFAOYSA-N;

Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19.^[2]^[3]^[4]^[5] It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor.^[6]^[7] It is taken by mouth.^[8]^[9]^[10]

The most common adverse events include transient decreases in high-density lipoprotein and increases blood triglycerides.^[8]

^ Cite error: The named reference NHK WORLD 2024 was invoked but never defined (see the help page).
^ McCarthy MW (December 2022). "Ensitrelvir as a potential treatment for COVID-19". Expert Opin Pharmacother. 23 (18): 1995–1998. doi:10.1080/14656566.2022.2146493. PMID 36350029. S2CID 253418404.
^ Fujikawa M (22 November 2022). "Japan Approves First Homegrown Covid-19 Antiviral Pill". The Wall Street Journal. Retrieved 28 November 2022.
^ "Shionogi's Covid antiviral lands first approval in Japan's new emergency approval pathway". Endpoints News. 22 November 2022. Retrieved 28 November 2022.
^ "Xocova: Powerful New Japanese Pill for Coronavirus Treatment". BioPharma Media. February 2022.
^ Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, et al. (May 2022). "Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19". Journal of Medicinal Chemistry. 65 (9): 6499–6512. doi:10.1021/acs.jmedchem.2c00117. PMC 8982737. PMID 35352927.
^ "Shionogi presents positive Ph II/III results for COVID-19 antiviral S-217622". thepharmaletter.com. 31 January 2022.
^ ^a ^b "Xocova (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection, under the Emergency Regulatory Approval System". Shionogi (Press release). 22 November 2022. Retrieved 28 November 2022.
^ "Shionogi's new COVID pill appears to ease omicron symptoms". Nikkei Asia. 21 December 2021.
^ Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. (IASO study team) (May 2022). "Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2". Nature. 607 (7917): 119–127. Bibcode:2022Natur.607..119U. doi:10.1038/s41586-022-04856-1. PMC 10579982. PMID 35576972. S2CID 248833104.

[NHK_WORLD_2024-1] Cite error: The named reference NHK WORLD 2024 was invoked but never defined (see the help page).

[pmid36350029-2] McCarthy MW (December 2022). "Ensitrelvir as a potential treatment for COVID-19". Expert Opin Pharmacother. 23 (18): 1995–1998. doi:10.1080/14656566.2022.2146493. PMID 36350029. S2CID 253418404.

[WSJ_20221122-3] Fujikawa M (22 November 2022). "Japan Approves First Homegrown Covid-19 Antiviral Pill". The Wall Street Journal. Retrieved 28 November 2022.

[Endpoints-4] "Shionogi's Covid antiviral lands first approval in Japan's new emergency approval pathway". Endpoints News. 22 November 2022. Retrieved 28 November 2022.

[5] "Xocova: Powerful New Japanese Pill for Coronavirus Treatment". BioPharma Media. February 2022.

[pmid35352927-6] Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, et al. (May 2022). "Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19". Journal of Medicinal Chemistry. 65 (9): 6499–6512. doi:10.1021/acs.jmedchem.2c00117. PMC 8982737. PMID 35352927.

[7] "Shionogi presents positive Ph II/III results for COVID-19 antiviral S-217622". thepharmaletter.com. 31 January 2022.

[Shionogi_PR_20221122-8] "Xocova (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection, under the Emergency Regulatory Approval System". Shionogi (Press release). 22 November 2022. Retrieved 28 November 2022.

[9] "Shionogi's new COVID pill appears to ease omicron symptoms". Nikkei Asia. 21 December 2021.

[pmid35576972-10] Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. (IASO study team) (May 2022). "Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2". Nature. 607 (7917): 119–127. Bibcode:2022Natur.607..119U. doi:10.1038/s41586-022-04856-1. PMC 10579982. PMID 35576972. S2CID 248833104.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]